| B21 | Prediction of coronary artery disease in high-risk people living with HIV in Asia | E-poster | Cardiovascular disease |
| B23 | Ageing and renal insufficiency in persons living with and without HIV in AFRICOS | E-poster | Renal disease |
| B24 | Impact of COVID-19-related lockdown on the metabolic profile of people living with HIV in Argentina | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Dolutegravir-based regimen is associated with metabolic syndrome components among persons with HIV in sub-Saharan Africa | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight gain following the single substitution of TDF by TAF in people living with HIV (PLWH) in the French Dat'AIDS cohort | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight changes, metabolic syndrome and all-cause mortality in persons living with HIV | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Patterns of weight gain in Bictegravir/Emtricitabine/Tenofovir alafenamide (B) | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Does weight gain on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B) lead to metabolic syndrome? | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight gain or 'return to health'? Changes in body weight in aging people living with HIV compared with the general population from the German Ruhr-area over 5 years | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Low proportion of individuals develop Metabolic Syndrome (MetS) or hepatic fibrosis after switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in virologically suppressed patients: a post-hoc metabolic analysis | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |